- Home
- ZTEK vs MNPR Comparison
ZTEK vs MNPR Comparison
Compare ZTEK & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- MNPR
- Stock Information
- Founded
- ZTEK 2008
- MNPR 2014
- Country
- ZTEK Canada
- MNPR United States
- Employees
- ZTEK N/A
- MNPR N/A
- Industry
- ZTEK Major Chemicals
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- ZTEK Industrials
- MNPR Health Care
- Exchange
- ZTEK Nasdaq
- MNPR Nasdaq
- Market Cap
- ZTEK 116.6M
- MNPR 113.5M
- IPO Year
- ZTEK N/A
- MNPR 2019
- Fundamental
- Price
- ZTEK $1.03
- MNPR $30.68
- Analyst Decision
- ZTEK
- MNPR Strong Buy
- Analyst Count
- ZTEK 0
- MNPR 3
- Target Price
- ZTEK N/A
- MNPR $27.33
- AVG Volume (30 Days)
- ZTEK 42.0K
- MNPR 93.6K
- Earning Date
- ZTEK 02-11-2025
- MNPR 11-08-2024
- Dividend Yield
- ZTEK N/A
- MNPR N/A
- EPS Growth
- ZTEK N/A
- MNPR N/A
- EPS
- ZTEK N/A
- MNPR N/A
- Revenue
- ZTEK $29,132.00
- MNPR N/A
- Revenue This Year
- ZTEK N/A
- MNPR N/A
- Revenue Next Year
- ZTEK N/A
- MNPR N/A
- P/E Ratio
- ZTEK N/A
- MNPR N/A
- Revenue Growth
- ZTEK 8.15
- MNPR N/A
- 52 Week Low
- ZTEK $0.50
- MNPR $1.55
- 52 Week High
- ZTEK $1.59
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- ZTEK 47.23
- MNPR 76.63
- Support Level
- ZTEK $1.05
- MNPR $20.16
- Resistance Level
- ZTEK $1.16
- MNPR $25.97
- Average True Range (ATR)
- ZTEK 0.09
- MNPR 2.75
- MACD
- ZTEK -0.02
- MNPR 0.41
- Stochastic Oscillator
- ZTEK 10.71
- MNPR 90.25
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.